China's Zhipu eyes expansion via Belt and Road Initiative as global AI market heats up
The Belt and Road Initiative is an ongoing effort to link economies into a China-centred trade network, largely via state-backed megaprojects abroad. Belt and Road work could eventually
cost Beijing US$1 trillion to US$8 trillion over an unspecified period, the Centre for Strategic and International Studies think tank estimated in 2018.
Zhipu AI's plan reflects intensifying efforts by both Chinese and US companies to widen the adoption of their AI models and applications beyond their home markets.
At a trade event in
Singapore last month, a Zhipu AI executive revealed that the company has been pitching governments around the world to help them launch localised sovereign AI agents, according to a report by Reuters.
AI agents are programs that are
capable of autonomously performing tasks on behalf of a user or another system. Essentially, these agents create a plan of specific tasks and subtasks to complete a goal using their available resources.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
44 minutes ago
- South China Morning Post
Mainland Chinese market for weight loss and diabetes drugs to soon be more crowded: report
Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing pressure after Denmark-based Novo Nordisk's semaglutide product loses patent protection in China next year, according to Boston-based global consultancy L.E.K. Consulting. Novo Nordisk's patent will expire in 2031 in Japan and Europe and 2032 in the US, according to its latest annual report. 'The landscape in China is expected to become even more competitive than in developed markets, where the GLP-1 category is primarily dominated by leading multinational pharmaceutical companies,' said Helen Chen, L.E.K.'s global healthcare and life sciences co-head, in a report on May 15. GLP-1 drugs mimic natural hormones, which signal the pancreas to release more insulin when blood-sugar levels are high, and also support weight loss by slowing digestion and reducing appetite. 04:12 One reporter's weight-loss journey and what a 'healthy body' means to him One reporter's weight-loss journey and what a 'healthy body' means to him Driven by sales growth of semaglutide, Novo Nordisk became the 10th largest drug company in the world in terms of revenue. London-based consultancy Evaluate said the firm's revenue rose 25 per cent to US$42.1 billion last year.
South China Morning Post
an hour ago
- South China Morning Post
Hong Kong to stick with 2% to 3% growth goal despite strong first quarter: Chan
Hong Kong will maintain its economic growth target of between 2 and 3 per cent for this year, the city's finance chief has said, while describing the anticipated rapid gains in the first quarter as an 'exception' rather than the norm. Financial Secretary Paul Chan Mo-po also said on Monday that authorities would 'prepare for the worst' despite the easing of tariffs amid the US-China trade war, but added that the recent rise in tourism would help offset sluggish domestic consumption. The government earlier set its growth forecast for gross domestic product at between 2 and 3 per cent for the year, following a 2.5 per cent year-on-year expansion in 2024. 'The overall growth forecast has not been adjusted upwards despite [the first quarter's] performance,' Chan told lawmakers on Monday. 'That's because the rapid growth in the first quarter was the exception rather than the norm, and there may be wild changes in the US government's policy. 'So we have to manage our risks. We have to prepare for the worst.'
South China Morning Post
an hour ago
- South China Morning Post
Chinese biotech firm Akeso tumbles on US partner Summit's setback for cancer drug
Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation's pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick US regulatory approval. Advertisement Akeso's shares fell 11.6 per cent to HK$73.65 in the morning session on Monday. US partner Summit Therapeutics' Nasdaq-listed shares slumped 30.5 per cent on Friday to US$18.22, the lowest since April 9. Summit said on Friday that the US Food and Drug Administration (FDA) indicated that a 'statistically significant' benefit on overall survival – from start of treatment to death – was required to support marketing approval for the ivonescimab antibody. Ivonescimab targets non-small cell lung cancer patients whose tumours showed a genetic abnormality that drives unusual cell growth. Akeso is based in Zhongshan in China's southern Guangdong province. Photo: Handout Summit said the first global phase-three clinical trial of Akeso's ivonescimab showed that it was effective in restoring patients' immune systems capabilities to attack tumour cells and slowed tumour progression. But ivonescimab had not yet demonstrated a survival benefit for patients in the study.
